Study Protocol
Accepted on 28 Apr 2026
Sintilimab plus fruquintinib with or without radiotherapy for third-line treatment of colorectal cancer with liver metastases: study protocol for a randomized controlled, multicenter phase II trial
in Cancer Immunity and Immunotherapy